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Objectives: A longer-acting injectable contraceptive that lasts for 6 months would be a valuable addition to the contraceptive method mix
and ideal for women who are interested in spacing births and/or uncertain about their future reproductive plans. Here we review past
applications of drug delivery technologies to injectable contraceptives as well as recent advancements in sustained drug delivery technologies
that hold promise for the development of a new longer-acting injectable contraceptive product.
Study design: A global landscape analysis was conducted, promising sustained drug delivery technologies, and research opportunities and
partnerships were establishedwith experts in the fields of contraception and drug delivery to identify new approaches in developing a longer-acting
injectable contraceptive product.
Results: The landscape analysis confirmed that a number of existing polymer systems, such as poly-lactic-co-glycolic acid and poly(epsilon-
caprolactone), remain promising candidates for application to a longer-acting injectable product. Novel polymers and materials also hold
promise for achieving longer release profiles and/or having other advantages over existing polymer systems, but products using these
materials could potentially have longer roads to regulatory approval. Additionally, recent advancements in the manufacturing process of
microspheres may benefit the development of a longer-acting injectable contraceptive.
Conclusion: The design of any new injectable product must take into account the limitations of current injectable contraceptives and address
concerns that women may have for a longer-acting product. FHI 360 is supporting several research collaborations for proof of concept of
various drug delivery approaches for achieving longer-acting product that fits an established target product profile.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Injectable contraceptives; LARCs; Research and development; Drug delivery1. Introduction
The unequivocal role of long-acting reversible contracep-
tives (LARCs) in reducing the rates of unintended pregnancies
has been demonstrated in numerous research studies and iswell
documented [1–4]. In recognition of their unique place in
public health programs, especially in developing countries,
international donors, service providers and philanthropic
organizations have devoted major attention and resources in⁎ Corresponding author. 359 Blackwell Street, Suite 200, Durham, NC
27701, USA. Tel.: +1-919-544-7040x11370.
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0010-7824/©2015TheAuthors. PublishedbyElsevier Inc.This is anopenaccess article unincreasing worldwide access to LARCs [5,6]. In some cases,
however, currently available LARCs are either unaffordable or
do not meet women's needs or preferences [7]. New reversible
productswith durations between the current 3-month injectable
contraceptives and contraceptive implants and intrauterine
devices would fill an important gap in the existing contracep-
tive method mix and would increase choices for women.
Injectable contraception has been a cornerstone of
international family planning programs for decades. Currently,
over 40 million women worldwide use injectable contracep-
tives to prevent pregnancy [8]. In sub-Saharan Africa, more
than one third of modern method contraceptive users rely on
injectable contraceptives [9]. Depending on the formulation,
currently available injectables are effective for 1–3 months,
requiring women to return to their provider monthly order theCCBY-NC-NDlicense (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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these methods [10]. Despite the broad and increasing use of
injectables, discontinuation and late return rates for reinjection
are high, frequently due to users' difficulty complying with
reinjection schedules [11].
Previous research has demonstrated that injectable
contraceptives with a longer interval between injections
lead to better adherence and continuation rates when
compared to those with shorter intervals. Ruminjo et al.
showed that the 1-year continuation rate was higher for a
3-month injectable depot medroxyprogesterone acetate
(DMPA) than for 1-month Cyclofem; the main difference
stated by study participants was logistical difficulty in
making frequent clinic visits [12]. South African researchers
compared DMPA 150 mg given every 3 months and DMPA
450 mg given every 6 months and demonstrated a
significantly better acceptability of the 6-month regimen
due, primarily, to convenience and reduced travel costs [13].
These findings are echoed by research on the acceptability of
longer-acting injectable (LAI) formulations in other thera-
peutic areas [14].
A LAI contraceptive that lasts for 6 months would be a
valuable addition to the method mix and ideal for women
who are interested in spacing births and/or uncertain about
their future reproductive plans. In addition to advantages for
users, these methods would reduce the patient load burden
on clinical facilities and community-based programs. Here
we review past applications of drug delivery technologies to
injectable contraceptives and review advancements in
sustained drug delivery technologies that hold promise for
the development of a new LAI contraceptive product.2. Background
A substantial amount of research has been conducted in the
last four decades to develop a longer-acting platform for the
release of contraceptive progestins using an injectable method
of administration. Historically, two approaches have been used
to extend duration of efficacy following the single adminis-
tration of a contraceptive drug: those involving the active
pharmaceutical ingredient (API) and those involving the
delivery system. The API approach involves identifying
new chemical entities with longer duration of efficacy, using a
higher dose or altering the method of administration. In
an effort to develop an alternative progestin-only injectable
that would produce a superior pharmacokinetic profile, have
fewer side effects and potentially have longer duration of
action than 3-month DMPA and 2-month norethisterone
(NET) enanthate (EN), theWorld Health Organization Special
Programme of Research in Human Reproduction launched a
major initiative in 1975 aimed at the chemical synthesis and
screening of a large number of progestin derivatives [15]. This
effort focused on creating long-acting esters of known steroids
[norethisterone and levonorgestrel (LNG)] that would be
formulated as 3- to 6-month injections to be used in women.Hundreds of compounds were synthesized and screened as part
of this large-scale initiative and several compounds proved to
be promising and longer acting than DMPA and NET-EN,
including LNG butanoate (LNG-B), LNG cyclopropyl-
carboxylate and LNG cyclobutyl-carboxylate. However,
because of financial constraints, only LNG-B has been
advanced to the dose-finding stage of clinical testing [16].
Higher doses of a known drug may also provide a longer
effect. For example, higher doses of DMPA (300/400 mg)
administered every 6 months provided effective contraceptive
protection in a clinical trial setting (this higher-dose DMPA
formulation was never marketed) [17–19]. An alternate route
of administrationmay be another way of extending duration of
action of an injectable steroid. For example, subcutaneous
administration of 104 mg DMPA is characterized by slower
absorption and more sustained release when compared to
intramuscular injection (im) of 150 mg DMPA [20].
The delivery system approach uses innovative technologies
to control the rate of drug release to achieve a longer period of
efficacy. The use of biodegradable polymers in the form of
microspheres and in situ forming depots in other therapeutic
areas have effectively reduced the dose of API compared to
more frequently administered suspensions of the same drug
[21]. Similarly, as described below, these systems have
demonstrated the potential to extend the release of contracep-
tive hormones in order to achieve a longer duration of action
from a single injection without increasing the dose of API.3. Past research
Microspheres are a drug delivery technology used in drug
products for a wide variety of clinical indications. Fabricated
as either solid spheres with a uniform dispersion of API in a
polymer matrix or a hollow polymer structure encapsulating
the API of interest, these biodegradable structures can be
loaded with a wide array of drugs, including hormones and
other small molecules, proteins and nucleic acids (Fig. 1).
Once injected into the body, microspheres provide a more
uniform release of an API for up to several weeks or months
from the site of injection through diffusion of the drug
through the polymer matrix and/or by gradual degradation of
the polymer matrix over time. Controlling the rate and
duration of release of API from microspheres is rather
complex but can be achieved through modification of the
polymer composition, the molecular weight of the polymers,
the microsphere particle size and amount of API loaded into
the microspheres, among other variables [22].
Over the past three decades, a number of microsphere
formulations using various biodegradable materials were
evaluated for controlled delivery of contraceptive hormones in a
preclinical setting. Three months of sustained release of LNG
was demonstrated in mice using a biodegradable polymer,
poly(3-hydroxybutyrate) [23]. Poly(epsilon-caprolactone)
(PCL), a synthetic biodegradable polymer that exhibits
slow degradation properties, has been used in an injectable
Fig. 1. PLA/PLGA microspheres loaded with LNG for controlled drug
delivery (photo courtesy of Dr. Linglin Feng, Shanghai Institute of Planned
Parenthood Research).
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combined with ethinyl estradiol (EE) [24,25]. The same
polymer was previously used to release LNG from the
biodegradable implant, Capronor [42]. This product, developed
by RTI International, with support from the National Institutes
of Health, was a single, tubular implant able to achieve up to
1 year of ovulation suppression. Despite showing promise
for being an effective contraceptive [43–45], its further
development was impeded by difficult removal of the implant
after a period of time and a long release tail [46].
Microspheres composed of the synthetic polyesters
poly(glycolide) (PLG), poly(lactide) (PLA) and their copolymer
poly-lactic-co-glycolic acid (PLGA), however, have become the
most common polymers due to their biocompatibility, biode-
gradability andmechanical strength. PLGAbecamewell known
after Lupron Depot (Abbott Laboratories, Abbott Park, IL,
USA), a 1–3 monthly formulation of PLGA microspheres
releasing leuprolide acetate for the treatment of advanced
prostate cancer inmen and endometriosis and fibroids inwomen
and became the first PLGAmicrosphere product to be approved
by the Food and Drug Administration in 1989. Since then,
PLGA has been used in a number of other drugs, including
Vivitrol (Alkermes, Waltham, MA, USA) for treatment of
alcohol dependence and Sandostatin LAR Depot (Novartis,
Basel, Switzerland) for treatment of acromegaly, among others.
In contraceptive research, PLG, PLA and PLGA have
shown promise for the controlled release of LNG both in vitro
and in vivo [26–31]. Additionally, PLGA microspheres have
been evaluated in vivo for delivery of Nestorone, a potent
contraceptive progestin being developed by the Population
Council in a variety of formulations. Results from this
formulation demonstrated effective serum levels of the
progestin for up to 28 days, albeit with highly variable serumlevels detected up to 196 days [32]. The most notable progress
with PLGA was achieved with microspheres releasing NET
that produced a promising release profile and a pharmacody-
namic response of up to 6 months in animal and early clinical
studies [33,34]. Later, a 90-day injectable formulation
containing either 65 or 100 mg NET (NET-90) was shown to
be effective in two larger clinical trials [35,36]. However,
manufacturing issues with the product scale-up ultimately
halted further progress with the NET-90 product.
In situ forming biodegradable systems have also been shown
to be effective for sustained drug delivery of contraceptive
hormones. These types of delivery systems consist of a drug and
biodegradable polymer suspended in a biocompatible organic
solvent. They are prepared as fluid formulations but form a
semisolid or gel depot at the site of injection after administration
[37]. A number ofmethods are employed to establish the in vivo
depot. These include a solvent removal method that relies on
water penetration in situ to separate the organic solvent from the
biodegradable polymer carrier (a process referred to as “phase
separation”), the introduction of chemicals to cross-link polymer
monomers and the use of thermosensitive biodegradable
triblock copolymers, which polymerize at body temperature to
form a gel [38]. In situ forming systems are able to provide
extended release profiles, some significantly longer than
microsphere formulations. One successful application of in
situ forming systems is the Atrigel® Delivery System (QLT,
Inc., Vancouver, Canada) that utilizes the phase separation
method to precipitate a depot of a PLGA matrix enclosing the
API. Eligard® (Sanofi US, Bridgewater, NJ, USA) uses the
Atrigel® system to deliver leuprolide acetate for palliative
treatment of advanced prostate cancer, endometriosis and
fibroids, with dosing available for 1, 3, 4 or 6 months.
Several groups have investigated the potential of in situ
forming biodegradable depots for sustained delivery of
contraceptive steroids in animals. Gao et al. studied various
oil and gel formulations both in vitro and in vivo,
demonstrating over 5 weeks of estrous suppression in rats
receiving formulations with LNG or EE [39,40]. The use of
an injectable gel matrix composed of PLGA was also
assessed in cotton-top tamarins for sustained delivery of
LNG, with duration of effectiveness reaching 28 weeks [41].4. Current trends
Except for a few isolated research activities, large-scale
funding and coordinated efforts to develop a LAI contracep-
tive based on biodegradable polymers have been suspended or
stopped altogether for various reasons, including technical
and funding challenges. Also, the introduction in the mid-late
90s of single and two-rod contraceptive implants that last for
3–5 years, but which are relatively easy to remove, temporarily
diminished donor interest in this area. However, limited access
to medical care in low-resource settings has recently reignited
interest of the donor and research communities in longer-term
contraceptive options that are easy to administer and do not
ig. 2. Optical microscope image of porous silicon microparticles,
pproximately 40 μm in diameter (photo courtesy of Dr. Michael Sailor,
niversity of California San Diego).
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in the political and financial climate in the family planning
arena worldwide have resulted in renewed interest in
contraceptive research and development [42]. Combined,
these trends contribute to an environment favorable to the
development of new and improved contraceptive products.
Moreover, with the increased popularity and success of
injectable contraceptives in recent years [43], the case for
the development of a new LAI contraceptive product is
strong. This may be achieved by capitalizing on new
developments in controlled release drug delivery for other
indications that have occurred in the last decade as well as
developing alternative lower-dose formulations to the
currently approved suspensions.
In 2011, with financial support from the Bill & Melinda
Gates Foundation, FHI 360, began work to develop a LAI
contraceptive product. The main goal of this project is to
bring to market a safe and effective injectable method that
would provide 7 months of contraceptive protection (6months
plus a 1-month window for reinjection) to women in the
developing world. Through this initiative, FHI 360 conducted
a landscape analysis of promising sustained drug delivery
technologies and research opportunities and established
partnerships with experts in the fields of contraception and
drug delivery.
The landscape analysis confirmed that PLGA remains a
promising synthetic polymer that can be applied to the
development of a LAI contraceptive product. Degradation
rates of this polymer can bemanipulated by adjusting the ratios
of PLA and poly(glycolic acid), a characteristic that makes
PLGA a polymer of choice for use in a longer-acting drug
delivery product. PCL, in spite of the challenges experienced
with developing the Capronor product, remains a promising
polymer that could be used in a LAI product. In addition to
exhibiting slower degradation relative to other biodegradable
polymers, the use of PCL in microsphere formulations is
advantageous due to its permeability to small drug molecules,
biocompatibility and exceptional ability to form blends with
other polymers.
The use of novel polymers andmaterials is appealing for the
development of a longer-acting product, given the unique
chemical properties that could potentially achieve longer
release profiles and/or have other advantages over the use of
PLGA and PCL. One alternative, for example, are polyanhy-
drides that have been assessed for parenteral delivery of drugs
for a variety of indications including local anesthetic agents,
anticancer agents, antibiotics and growth hormone. A major
advantage of this class of polymer is the ease of varying the
rate of degradation and release by adjusting the ratio of its
prepolymer monomers [44].
An alternative material to polymers for use in controlled
drug delivery applications is porous silicon (Si), which can be
loaded with a wide range of molecules (Fig. 2). Porous Si is
produced by electrochemical “etching” of crystalline silicon
wafers, resulting in porous silicon microparticles with precise
pore size and distribution. In addition to being able to vary theF
a
Umicroparticle pore size and volume, advantages to the system
include large surface area of the microparticles, the ability to
modify the surface to control drug release properties,
resorbability and biocompatibility [45]. The degradation
product of porous Si microparticles is orthosilicic acid
[Si(OH)4], which is the natural form of Si found in the body
and is readily excreted by the kidneys. Porous Si has been
investigated for controlled delivery of various drugs as well as
proteins, enzymes and genes, with release profiles reaching
weeks to several months [46].
In addition to new materials, advancements in the
manufacturing process of microspheres may benefit the
development of a LAI contraceptive. A major limitation to
more traditional emulsion-based methods of microparticle
fabrication such as spray drying, solvent evaporation and
solvent extraction is the production of broad particle size
distributions. Microsphere particle size has a significant
impact on release and degradation profiles as smaller particles
tend to degrade and release loaded drug faster due to larger
surface-to-volume ratio. Therefore, formulations that have a
narrower microsphere particle size distribution will allow
greater control over the API release profile including
decreasing the initial burst release and shortening the “tail”
of the release profile (i.e., the period when blood levels of the
API are still detectable but not sufficient enough to be
effective). Recent work has been carried out to narrow the
particle size distribution through the development of new
manufacturingmethods.One such innovation, called Precision
Particle Fabrication (PPF), is able to create monodispersed,
drug-loaded microparticles by using acoustic excitation to
produce uniform-sized droplets of a polymer-containing
solution in a nonsolvent carrier stream [47]. This technology
has been used to create precise particle sizes with a wide range
of polymers containing a number of different drugs, including
rhodamine B and piroxicam, with release profiles reaching
several months with certain formulations (Fig. 3) [48,49].
Fig. 3. Monodispersed microparticles fabricated using PPF technology
(photo courtesy of Orbis Biosciences, Inc.).
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technologies and approaches holds significant promise to
develop a LAI contraceptive product.5. Path forward
Despite the potential user and programmatic advantages
of a 6-month injectable, a potential challenge to broad use
may be concern over the “irreversibility” of these systems. If
women using such a product develop serious side effects,
such as hormonally responsive cancers or other conditions in
which hormonal therapies would be contraindicated, the
method could not be discontinued immediately. Also, less
serious side effects such as irregular menstrual bleeding
could be a source of dissatisfaction, but users could not
discontinue immediately. To address this potential concern, a
shorter duration of contraceptive protection was chosen over
longer-term duration (i.e., 6 months versus 12 or 18 months)
to guide the LAI product development process. Patient
counseling about possible side effects including bleeding
disturbances will remain an important tool to prevent user
dissatisfaction with the new LAI product and future
discontinuation [50,51]. In addition, biodegradable drug
delivery systems have been historically characterized by a
long release tail [52]. Long periods of subtherapeutic drug
levels at the end of product duration could make it difficult to
predict return of fertility for women who want to conceive, a
concern often cited by users and medical professionals as a
serious downside of current injectable options.
The design of any new injectable product must take into
account these concerns. Additionally, as the majority of
injectable contraceptive users are in developing areas of the
world, design and manufacturing of the product must ensure
affordability and stability under extremes in temperature and
humidity and must allow for easy storage and distribution in
low-resource settings. To this end, FHI 360 developed a target
product profile that will guide development of a 6-month
contraceptive product. The goal is for the method to provideeffective levels of drug for 7 months (6-month duration with a
1-month grace period to return for reinjection), a predictable
return of fertility (well defined “tail”) and acceptable side
effects and contraindications. The final product should be
easily suited for self-administration and/or administration by
lower cadres of health care workers in developing settings to
facilitate wide uptake of the method (e.g., a disposable
prepackaged syringe or autodisable injection system similar
to Uniject™).
Developing a product that meets these requirements is a
difficult task.While newer APIsmay offer advantages over the
currently approved progestins in terms of side effects, our goal
for a first-generation LAI is to utilize a well-established
contraceptive hormone. To facilitate regulatory approval, the
choice ofAPIs that are, or soonwill be, approved by a stringent
regulatory authority seems prudent. With this in mind, LNG
and etonogestrel (ENG), which are well-characterized proges-
tins with robust safety profiles and a history of use in
longer-acting contraceptive methods, are the drugs of first
choice [53,54]. From the newer generation of progestins,
Nestorone being developed by the Population Council in other
presentations could be a promising candidate due to its unique
biologic profile and clinical performance [55,56]. Marketing
approval for a Nestorone-containing contraceptive vaginal
ring is pending [57].
The use of new polymer systems, while promising, may
require extensive toxicity and carcinogenicity studies to
obtain regulatory clearance that may substantially prolong
the approval process. As with selection of the API, the first
generation of a LAI will likely utilize well-characterized
PLG, PLA, PLGA and PCL that have been approved and
used in existing marketed drug products.
Another important consideration for the development
and introduction of a LAI contraceptive is whether recent
controversy regarding a possible association between
hormonal contraceptives and HIV acquisition could impact
introduction or acceptability of a new injectable product
[58]. Product developers will need to carefully monitor
emerging evidence in this area, as well as how new findings
may influence public opinion.
As part of the LAI project, FHI 360 is supporting research
collaborations at the Shanghai Institute of Planned Parenthood
Research, Orbis Biosciences, Inc., the University of California
San Diego and the University of Tennessee Health Science
Center. These groups are investigating the following drug
delivery systems: (1) PLA/PLGA microspheres releasing
LNG, (2) PLGA microspheres releasing ENG, (3) nanostruc-
tured porous silicon microparticles releasing various contra-
ceptive steroids and (4) an in situ gelling PLGA/PLA
suspension releasing LNG, respectively. Interim results of
these studies will be available in 2015, and final results will be
available in 2016. The goal is to develop and bring to market a
6-month injectable within 10–15 years and possibly sooner.
An injectable that lasts 6 months would provide women with
greater choice, offer an intermediate duration of efficacy
between short- and long-acting reversible methods, improve
8 V. Halpern et al. / Contraception 92 (2015) 3–9continuation and compliance and ultimately help reduce rates
of unintended pregnancy around the world.
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